Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
congrats to the .0008 loaders, thatll be a nice trade in the coming weeks.
still waiting on reversal candle for entry. Nice rebound with the hammer but not enough, the trend continues....
How is a 5 billion share o/s a GOOD thing?
let me explain, given the market cap has gone from $600K to $2,493,318 in two weeks, there is no room for downward pressure, weve also traded over 500M shares past two days almost hitting 1B on monday, ide säy they were expecting a big crowd AND THEY GOT IT.
How is a locked OS bad?? they cant dilute the market, this is huge, ONTOP of that they will be retiring 300M of that locked OS, this has got so much úpside potential its only a matter of time, the markets waking up here. but i admîre a devil's advocate. go on ....
A reverse split would be a good idea. Sooner or later, it'll be necessary.
No, thats fear, lets take a look whäts really happening instead of throwing out worst case scenarios at an undervalued price.
http://www.newschannel6now.com/story/35377448/mccusker-holdings-corp-announces-share-retirement-mitigated-debt-status-and-acquisition-strategy
http://www.24-7pressrelease.com/press-release/mccusker-holdings-corp-announces-share-retirement-mitigated-debt-status-and-acquisition-strategy-438133.php
https://twitter.com/mccuskerco
http://www.mccuskerco.com/press_releases
-debt free
-share retirement
-cash on hand
MMs stalling the run today
GOOD FORM, release the kräken!
nice green solid reversal candle in play, need the PM session to confirm or the ask wall to fall.
the monster begins to awaken once again...
nice post steve ive been checking every day, itching to jump back in when this downtrend reverses.
nice chart even better app on the way
bounce alert high, next three days are crucial. these note conversions are deadly. this snaps when ño one expects it, its overdue.
ill take 2M of the scam de jour served with extra scam sauce hold the onions.
amazing, orrv/mccu is golden
to the 3s!
shes a tricky one, this should be the last r/s dûe to timing of their studies completion and whats happening in the industry, but who knows, should get interesting after the r/s settles. settles where you might ask, i might reply; i have no clue. thats the rîsk.
it doesnt matter who we are, what matters is our plan, here feed ôff my bull crumbs, now is not the time for fear, that comes later.....
NMUS
NEMUS BIOSCIENCE INC
Business Overview
We are a biopharmaceutical company focused on the discovery, development, and the commercialization of
cannabinoid-based therapeutics through our partnership with the University of Mississippi, or UM. UM has held the
only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968, and it has
significant expertise in cannabis cultivation and the extraction, separation, process and manufacture of cannabis
extracts containing cannabinoid molecules. We are currently UM’s sole partner for the development and
commercialization of drugs derived from cannabis extracts, or cannabinoids.
Our Strategic Partnership
In July 2013, we entered into a Memorandum of Understanding, or MOU, with UM to engage in joint research
activities including extracting, manipulating, and studying cannabis in every form to develop intellectual property
with the intention to create and commercialize therapeutic medicines. The MOU provides that we own all
intellectual property developed solely by our employees and will jointly own all intellectual property developed
jointly between Nemus Sub and UM employees. The term of the agreement is five years and the parties agreed to
enter into separate research agreements upon the identification of patentable technologies. The agreement may be
terminated by either party with three months’ written notice to the other party.
Our Product Candidates
Cannabinoids are a class of chemically diverse compounds that are found in extracts from the cannabis plant. These
compounds express their physiological response by binding to specific cannabinoid receptors (CB1 and CB2), which
are found throughout the body. Some cannabinoids have been observed to exert multiple effects on the human body,
including but not limited to: impacting the immune response, nervous system function and repair, gastrointestinal
maintenance and motility, motor function in muscles, pancreatic functionality and blood sugar regulation, and
integrity of function in the eye, including the optic nerve. Cannabis and specific cannabinoids have been studied
widely, with published data suggesting the potential for these compounds to be used in treating many disorders or
alleviating disease-associated symptoms.
We are focused on the development of early stage cannabinoid product candidates. Specifically, UM’s research to
date has indicated that proprietary cannabinoid chemistry coupled with the innovative, alternative delivery methods,
such as ocular, transmucosal and trans-rectal delivery, could have beneficial effects across a spectrum of diseases,
including these primary targets:
· Glaucoma and other ocular-related disorders;
· Palliative care associated with adverse events related to chemotherapy; and
· Anti-infective activity directed against MRSA.
The following table summarizes certain information regarding our cannabinoid product candidates:
Product Candidate Indication Development Status
NB1111 Glaucoma Preclinical
NB1222 Chemotherapy Induced Nausea and Vomiting
(CINV)
Preclinical
NB3111 MRSA Preclinical
NB2111 Chemotherapy Induced Peripheral Neuropathy
(CIPN)
Research
NB2222 Ocular Targets: Uveitis, Dry Eye Syndrome,
Macular Degeneration, Diabetic Retinopathy
Research
Our Business Strategy
Our goal is to become the premier developer of prescriptive cannabinoid-based medicines for global markets with
significant unmet medical needs. Our current operating strategy includes:
· selection of potential clinical targets based on internal and external published data, access to
appropriate cannabinoids, and the impact of both developmental and market conditions;
· prioritization of product candidates based on associated target indications;
· utilization, where feasible, of naturally-derived drug prototypes leading to synthetically produced
cannabinoids for development and commercialization;
· development and execution of an intellectual property strategy;
· development and advancement of our current product pipeline;
· outsourcing services, such as use of Clinical Research Organizations, or CROs, and contract
manufacturers for the active pharmaceutical ingredient, or API, where possible and appropriate;
· obtaining regulatory approval from the FDA and European Medicines Agency, or EMA, for product
candidates;
· research and development of additional target indications for cannabinoid product candidates; and
· partnering, out-licensing, or selling approved products, if any, to optimize Company efficiencies to
bring state-of-the-art therapeutics to patients.
Sales and Marketing
We have not established a sales, marketing or product distribution infrastructure because our lead candidates are still
in discovery or preclinical development. If and when we obtain approval to market any of our product candidates,
we will evaluate what we believe to be the optimal commercialization path for the company, the respective product
candidate, and patients. Commercialization paths may include licensing, selling, or partnering with other
commercial partners. We may also choose to build a commercial sales and marketing team for some or all of our
product candidates.
Manufacturing
We do not own or operate, and currently have no plans to establish, any manufacturing facilities for final
manufacture. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product
candidates for preclinical and clinical testing, as well as for commercial manufacture of any products that we may
commercialize.
We entered into an agreement with Albany Molecular Research Inc. (NASDAQ: AMRI) in February 2016 for
the development and manufacture of our proprietary cannabinoid-based active pharmaceutical ingredients
(APIs). It is anticipated that the synthetically generated API will form the basis of our drug candidates
NB1111, in development for glaucoma, and NB1222, in development for the management of CINV.
For all of our future product candidates, we aim to identify and qualify manufacturers to provide the API and
fill-and-finish services prior to submission of a new drug application, or NDA, to the FDA. We expect to continue to
develop drug candidates that can be produced cost-effectively at contract manufacturing facilities.
52-Week High 1.80
10/25/206
52-Week Low 0.24
03/28/201
7
Primary Exchange OTC Markets
Volume (10 day Average) 107,991
Volume (90 day Average) 196,537
Share Structure
Market Value
1 $7,195,504 a/o Apr 28, 2017
Authorized Shares 236,000,000 a/o Apr 28, 2017
Outstanding Shares 28,285,663 Float 14,218,313
Float percentage of
total shares
outstanding is the
percentage of float
shares relative to the
total shares
outstanding. As of
today?, Nemus
Bioscience Inc's float
percentage of total
shares outstanding is
65.70%?.
Short percentage of
float is the percentage
of shares shorted
compared to the float.
As of today?, Nemus
Bioscience Inc's short
percentage of float is
0.00%?.
Institutional ownership
is the percentage of
shares that are owned
by institutions out of
the total shares
outstanding. As of
today?, Nemus
Bioscience Inc's
institutional ownership
is 2.57%?.
WHO O?NS THE STÔCK?
Insider Ownership 45.4%
Top Insiders
Name Position Total Holdings
Last Transaction
Type
Last Transaction
Date
LAPHAM, REG ALEXANDER Beneficial Owner
(10% or more)
3,787,500.00 Disposition (Non
Open Market)
03/13/17
LYKOS, COSMAS N. Chairman 3,699,400.00 Acquisition (Non
Open Market)
10/20/15
SQUIRES, RICHARD D. Beneficial Owner
(10% or more)
1,485,000.00 --
MURPHY, BRIAN STUART Chief Executive
Officer
375,000.00 Acquisition (Non
Open Market)
10/20/15
INGRAM, DOUGLAS S. Vice Chairman 372,500.00 Acquisition (Non
Open Market)
10/20/15
BERECZ, ELIZABETH Chief Financial
Officer
350,000.00 Acquisition (Non
Open Market)
10/20/15
MCLAUGHLIN, GERALD W Director 61,250.00 Acquisition (Non
Open Market)
10/20/15
GEORGE, THOMAS Director 60,000.00 Acquisition (Non
Open Market)
10/20/15
MENDEZ, YOSBANI Beneficial Owner
(10% or more)
2,440.00 Disposition (Non
Open Market)
10/31/14
MENDEZ, FRANCISCO
JAVIER
Beneficial Owner
(10% or more)
0.00 Disposition (Non
Open Market)
10/31/14
c?ash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash
equivalents, and marketable securities divide by its debt. Nemus Bioscience Inc's cash to debt ratio for the
quarter that ended in Dec. 2016 was No Debt.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can
see, Nemus Bioscience Inc could pay off its debt using the cash in hand for the quarter that ended in Dec.
2016.
NMUS' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.36 Max: No Debt
Current: No Debt
NMUS's Cash-to-Debt is ranked ?higher? than
73% of the ?943? Companies
in the ?Global Biotechnology? industry.
( Industry Median: 54.02 vs. NMUS: No Debt )
LINKS AND LATEST NEWS FOR NMUS
https://www.otcmarkets.com/stock/NMUS/news
http://www.gurufocus.com/stock/NMUS
https://eresearch.fidelity.com/eresearch/evaluate/snapshot.jhtml?symbols=NMUS&opt=-1
#/research?symbol=NMUS
https://www.otcmarkets.com/stock/NMUS/profile
Diverting factual statements with sarcastic humor seems to be your MO. I have you pegged
lolllol you literally stated whät you are doing, nice try tho, i havent seen you post 1 factual post pertaining to the company, review my posts and come back with some real facts instead of personal attacks
simply put there is a reason for companies to go public, there îs älso a time for financing and a time to reap the rewards of that financing. imo the rewards arent paying off yet, if yôu review their financials they häve been loosing money every year for the past 3 yeärs only being able to stäy aflôat through convertible debt, also the UM contract ends 2018 sooooooooooo youll wait, wait a few years if you have that luxury. i doñt.
ALSO FROM THE 8K; READ FURTHER THAN THE 1ST PARAGRAPH.
SECURITIES PURCHASE AGREEMENT
THIS SECURITIES PURCHASE AGREEMENT (the “ Agreement ”) is dated as of May 3, 2017 (the “ Effective Date ”), between Nemus Bioscience,
Inc., a Nevada corporation (the “ Company ”), and Schneider Finance LLC, a Nevada limited liability company (the “ Purchaser ”).
WHEREAS, the Company and the Purchaser are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(2) of the Securities Act of 1933, as amended (the “ Securities Act ”), and Rule 506 of Regulation D promulgated thereunder;
WHEREAS, the Company has authorized a new series of its preferred stock, par value $0.001 per share, which shall be called the Company’s Series E
Preferred Stock (the “ Preferred Stock ”), and shall be convertible into shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”)
(as so converted, the “ Conversion Shares ”) in accordance with the terms of the Company’s Certificate of Designation in the form attached hereto as Exhibit A
(the “ Certificate of Designation ”);
WHEREAS, the Company desires to issue and sell 1,000,000 shares (the “ Preferred Shares ”) of the Company’s Preferred Stock at a purchase price of
$20.00 per Preferred Share (the “ Purchase Price ”) with a conversion price of $0.30 per Preferred Share (subject to adjustment as set forth in the Certificate of
Designation); and
WHEREAS, concurrently with the execution and delivery of the Agreement, and as a condition to the willingness of the Company to enter into the
Agreement, an affiliate of the Purchaser has entered into a guarantee dated as of the date hereof (the “ Guarantee ”), a copy of which has been delivered to the Company
(a) The Purchaser shall: (i) pay the Purchase Price by wire transfer of immediately available funds pursuant to the wire instructions provided by the
Company and (ii) deliver to the Company such other documents relating to the transaction as the Company or its counsel may reasonably request (the “
Transaction Documents ”).
(b) The Company shall: (i) execute and deliver the Transaction Documents to the Purchaser (ii) file or cause to be filed the Certificate of Designation with
the Secretary of the State of Nevada and (iii) deliver to the Purchaser stock certificates (in the denominations as the Purchaser shall request) representing the
Preferred Shares duly executed on behalf of the Company and registered on the books of the Company in the name of the Purchaser.
(c) Capitalization . The authorized capital stock of the Company consists of (i) 236,000,000 shares of Common Stock, of which as of March 31,
2017, 27,310,663 shares are issued and outstanding; 1,130,000 shares are issuable and reserved for issuance pursuant to outstanding stock options;
857,500 shares are reserved for future issuance under the Company stock option and/or purchase plans; 11,649,500 shares are issuable and reserved for
issuance pursuant to outstanding warrants; and 17,325,500 shares are issuable and reserved for issuance pursuant to securities (other than the Preferred
Shares) exercisable or exchangeable for, or convertible into, shares of Common Stock and (ii) 20,000,000 shares of preferred stock, of which as of the date
hereof, 3625.375 shares of Series B Preferred Stock and 706 shares of Series D Preferred Stock are issued and outstanding. All of such outstanding shares
have been and are, or upon issuance will be, validly issued, fully paid and nonassessable.
(d) Issuance of Securities . The Preferred Shares are duly authorized and, upon issuance in accordance with the terms hereof, shall be (i) validly
issued, fully paid and non-assessable, (ii) free from all taxes, liens and charges with respect to the issuance thereof and (iii) entitled to the rights and
preferences set forth in the Certificate of Designation. At least 66,666,667 shares of Common Stock have been duly authorized and reserved for issuance
upon conversion of the Preferred Shares. Upon conversion or exercise in accordance with the Certificate of Designation, the Conversion Shares will be
validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issuance thereof, with the holders being entitled
to all rights accorded to a holder of Common Stock. The issuance by the Company of the Securities is exempt from registration under the Securities Act.
The offer and sale by the Company of the Preferred Shares is being made in reliance upon the exemption from registration set forth in Rule 506 of
Regulation D and/or Regulation S under the Securities Act and is only being made to “accredited investors” that meet the requirements of Rule 501(a) of
Regulation D and similar exemptions under state law.
In the words of the sweet virgin mary.......COME ÄGÄIN????????
(Bane voice)'he takes his 20M dollar convertible debt and gives it back to you... THE PEOPLE.' -a necessary evil
its never been the fundamentals, its always been a price action play....sad volcano...sad.
Double bottom bounce off .0008 up trénd off .0004 still in tact giving the bears a false hope, charts dont lie.
my tents pitched, very interested.
massive stealth buying going on check A/D AND OBV BULLISH DIVERGENCE , TRIX agrees bottom in.
http://ih.advfn.com/p.php?pid=charts&symbol=NO%5EORRV
what a monster run off .002 using the 9day Ma support like a boss.
big boys are shôwing up, big plays usually follow
stuff most of us already know, no EXPLÔSIVE material. your day will come volcano....i also agree with a .025-.03 price target.
guaranteed you wont sell, this imaginary 25.8M is a cool story tho
come now surely you'll eventually realize that emotions are a costly thing to play out in the market, You have no clue who you are typing at, you sound like a gay boi when you try to insult people. try harder.
well well well if I buy .0004s and sell you .0004s NOBODY wins except the broker slippage. If you've got time to sit and wait I'm sure it will pay off, chew is Acting like you're the only one who knows how to play this game mayne.
Sorry boys No PR tommrow and I'm leaving the party and dumping my bag, sit on .0004s if you want it. PMEA doesn't know how to release a proper PR with full details which tells me either they don't know how the swap will happen; or they think spoon feeding the shareholders with "more details to come" will keep the carrot on the stick.
Hope for the best, plan for the worst.
observe the 1 month/30min chart, enjoy the ride, high probability the Momo phase will follow as planned.
the numbers cant lie, use the graph.
golfers clap nice call
thanks fôr checking me out pat! sorry i dont have time to respond to mundane noises from the crôwd, i have to actually trade
let the new cycle begin...RELEASE THE MCCU
BUCKLÉ UP LADIES